BeOne Medicines (SHSE:688235) COGS-to-Revenue : 0.15 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is BeOne Medicines COGS-to-Revenue?

BeOne Medicines's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥1,196 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥8,099 Mil.

BeOne Medicines's COGS to Revenue for the three months ended in Mar. 2025 was 0.15.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BeOne Medicines's Gross Margin % for the three months ended in Mar. 2025 was 85.23%.

BeOne Medicines COGS-to-Revenue Historical Data

The historical data trend for BeOne Medicines's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines COGS-to-Revenue Chart

BeOne Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.23

0.14

0.20

0.15

0.16

BeOne Medicines Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.17	0.15	0.17	0.14	0.15

BeOne Medicines COGS-to-Revenue Calculation

BeOne Medicines's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4325.384	/	27741.222
	=	0.16

BeOne Medicines's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1196.149	/	8099.491
	=	0.15

BeOne Medicines (SHSE:688235) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BeOne Medicines's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1196.149 / 8099.491
	=	85.23 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

BeOne Medicines COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BeOne Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (SHSE:688235) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 06160:Hong Kong 49B:Germany B1ME34:Brazil

Address

c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website

https://www.beonemedicines.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines